1-(s-butylamino)-2-dimethylaminoethane | 67651-83-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(s-butylamino)-2-dimethylaminoethane
• 英文别名: N-2-Dimethylaminoaethyl-N-sec-butylamin；N-butan-2-yl-N',N'-dimethylethane-1,2-diamine
• CAS: 67651-83-6
• 化学式: C₈H₂₀N₂
• mdl: MFCD09809478
• 分子量: 144.26
• InChiKey: OODSKLIZBOSXQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(s-butylamino)-2-dimethylaminoethane 在 正丁基锂 作用下， 以 正己烷 为溶剂， 反应 2.5h， 生成 (1-s-butylamide-2-dimethylaminoethane-N,N')lithium
  参考文献：
  名称：

  (AMIDE AMINO ALKANE) METAL COMPOUND AND METHOD OF PRODUCING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND

  摘要：

  公开号：

  EP2636674B1
• 作为产物：
  描述：

  2-溴丁烷 、 N,N-二甲基乙二胺 生成 1-(s-butylamino)-2-dimethylaminoethane
  参考文献：
  名称：

  Pagani,G. et al., Farmaco, Edizione Scientifica, 1978, vol. 33, p. 531 - 542

  摘要：

  DOI：

文献信息

• (AMIDE AMINO ALKANE) METAL COMPOUND, METHOD OF MANUFACTURING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND
  申请人：Fujimura Osamu

  公开号：US20130273250A1

  公开（公告）日：2013-10-17

  The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): wherein M represents a metal atom; R 1 represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms; R 2 and R 3 may be the same as, or different from each other, and each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, or R 2 and R 3 may form a substituted or unsubstituted 5- or 6-membered ring together with the nitrogen atom to which they are bound; Z represents a linear or branched alkylene group having 1 to 10 carbon atoms (a part of which may optionally form a ring); and n represents a number of the ligands, which is equal to the valence of the metal (M), and represents an integer of from 1 to 3; with the proviso that the metal compounds in which M is Li (Lithium), Be (Beryllium), Ge (Germanium) or Nd (Neodymium) are excluded; the metal compounds in which M is Mg (Magnesium) and R 1 is methyl group are excluded; the metal compounds in which M is Zn (Zinc) and R 1 is methyl group are excluded; the metal compounds in which M is Bi (Bismuth) and R 1 is t-butyl group are excluded; and in cases where n is two or greater, two or more ligands may be the same as, or different from each other; and a method of producing a metal-containing thin film using the metal compound.

  本发明涉及一种由式（1）表示的（酰胺氨基烷）金属化合物：其中，M代表金属原子；R1代表具有1至6个碳原子的线性、支链或环烷基；R2和R3可以相同，也可以不同，每个独立地表示具有1至3个碳原子的线性或支链烷基，或者R2和R3可以与它们所连接的氮原子一起形成取代或未取代的5-或6-成员环；Z代表具有1至10个碳原子的线性或支链亚烷基（其中的一部分可以选择地形成环）；n代表配体的数量，其等于金属（M）的价，表示为1至3的整数。但是，M为锂（Li）、铍（Be）、锗（Ge）或钕（Nd）的金属化合物被排除；M为镁（Mg）且R1为甲基基团的金属化合物被排除；M为锌（Zn）且R1为甲基基团的金属化合物被排除；M为铋（Bi）且R1为叔丁基基团的金属化合物被排除；在n为2或更大的情况下，两个或更多的配体可以相同或不同；以及使用该金属化合物制备含金属薄膜的方法。
• NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION
  申请人：KISSEI PHARMACEUTICAL CO., LTD.

  公开号：US20150315183A1

  公开（公告）日：2015-11-05

  [Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D 2 receptors. [Solution] The present invention provides a compound represented by the general formula (I): in which R 1 is C 1-6 alkyl or the like; R 2 is hydrogen or the like; R 3 and R 4 are each hydrogen, C 1-6 alkyl, R 10 R 11 N—C 1-6 alkyl, aralkyl, or the like; R 5 and R 6 are hydrogen or the like; and R 7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D 2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.

  [问题] 提供一种在多巴胺D2受体上表现出激动作用的新化合物。 [解决方案] 本发明提供一种由通式（I）表示的化合物：其中R1为C1-6烷基或类似物; R2为氢或类似物; R3和R4均为氢、C1-6烷基、R10R11N-C1-6烷基、芳烷基或类似物; R5和R6为氢或类似物; R7为氢或类似物，或其药学上可接受的盐，以及包含该化合物/盐和组合物的制药组合物。本发明的化合物表现出强效的多巴胺D2受体模拟活性，因此可用作治疗或预防帕金森病等疾病的药物。
• NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIVATIVE AND COMPOSITION
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP2930175A1

  公开（公告）日：2015-10-14

  [Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] The present invention provides a compound represented by the general formula (I): in which R1 is C1-6 alkyl or the like; R2 is hydrogen or the like; R3 and R4 are each hydrogen, C1-6 alkyl, R10R11N-C1-6 alkyl, aralkyl, or the like; R5 and R6 are hydrogen or the like; and R7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.

  [问题]提供一种对多巴胺 D2 受体具有激动作用的新型化合物。 [解决方案] 本发明提供一种由通式（I）表示的化合物： 其中 R1 是 C1-6 烷基或类似物；R2 是氢或类似物；R3 和 R4 分别是氢、C1-6 烷基、R10R11N-C1-6 烷基、芳烷基或类似物；R5 和 R6 是氢或类似物；以及 R7 是氢或类似物，或其药学上可接受的盐、含有相同物质的药物组合物以及所述化合物/盐和组合物的用途。本发明的化合物具有强效的多巴胺 D2 受体模拟活性，因此可用作帕金森病等的治疗或预防剂。
• US8871304B2
  申请人：——

  公开号：US8871304B2

  公开（公告）日：2014-10-28
• US9585885B2
  申请人：——

  公开号：US9585885B2

  公开（公告）日：2017-03-07